Malignant salivary gland tumor

Malignant salivary gland tumors are a heterogeneous group of epithelial neoplasms arising from major salivary glands (parotid, submandibular, sublingual) or from the hundreds of minor salivary glands distributed throughout the oral cavity, pharynx, and upper aerodigestive tract.[1][2] They account for approximately 3%–6% of all head and neck cancers and less than 1% of all human malignancies.[1][3] Biologic behavior ranges from indolent, low-grade carcinomas to rapidly fatal high-grade cancers, and is strongly influenced by histologic subtype and grade.[4][5] In the oral and maxillofacial region, these tumors most commonly present as submucosal palatal masses or, rarely, as primary intraosseous jaw lesions arising from entrapped salivary tissue or metaplastic odontogenic epithelium.[6][7] The signature dental radiographic pattern—when the jaws are involved—is a destructive radiolucency that may mimic an odontogenic cyst or tumor.[8][9] Complete surgical resection is the mainstay of treatment, with adjuvant radiotherapy indicated for high-risk features.[3][10]

Current Classification

The WHO Classification of Head and Neck Tumours (5th edition, 2024) recognizes over 20 malignant epithelial salivary gland tumor types.[4][11] Key entities include:

• Mucoepidermoid carcinoma (MEC) — the most common malignant salivary gland tumor overall[12][13]
• Adenoid cystic carcinoma (AdCC) — the most common malignant tumor of the minor salivary glands in many series[14][15]
• Acinic cell carcinoma
• Salivary duct carcinoma
• Carcinoma ex pleomorphic adenoma
• Polymorphous adenocarcinoma (formerly polymorphous low-grade adenocarcinoma)[16]
• Secretory carcinoma (formerly mammary analogue secretory carcinoma)[16]
• Adenocarcinoma, not otherwise specified (NOS)

Newly Recognized Entities

The 5th edition WHO classification introduced microsecretory adenocarcinoma, sclerosing microcytic adenocarcinoma, and mucinous adenocarcinoma.[11][17] Post-classification developments include palisading adenocarcinoma and microcribriform adenocarcinoma.[18]

Intraosseous Variant

Primary intraosseous (central) salivary gland carcinoma of the jaws is an accepted but exceedingly rare entity, with central MEC being the most common subtype, followed by central AdCC.[6][7]

• Incidence: Global annual incidence of all salivary gland tumors is estimated at 0.4–13.5 per 100,000; malignant tumors constitute roughly 20%–25% of all salivary gland neoplasms.[1][12]
• Age: Peak incidence in the fifth to seventh decades; mean age at diagnosis for malignant tumors is approximately 55–58 years. Pediatric cases are uncommon and predominantly low-grade MEC or acinic cell carcinoma.[14][19][20]
• Sex: Slight male predominance overall, though certain subtypes (e.g., central MEC) show a female predilection.[6][14]
• Anatomic distribution:
  • Parotid gland: ~70%–80% of all salivary gland tumors arise here, but only ~20% of parotid tumors are malignant.[21][22]
  • Submandibular gland: ~10%–15% of tumors; ~50% are malignant.[21]
  • Sublingual gland: rare, but 80%–90% of tumors are malignant.[14][23]
  • Minor salivary glands: ~47%–87% of tumors are malignant; the hard palate is the most common intraoral site.[14][21]
• Intraosseous tumors: Central MEC constitutes only 2%–3% of all MECs; the mandible is affected approximately three to four times more often than the maxilla, with the premolar-molar-angle region being the most common site.[6][7]

Presentation

Malignant salivary gland tumors typically present as a painless or painful mass in the affected gland or oral submucosal tissue.[24][25] Features suggestive of malignancy include:

• Rapid growth, firmness, and fixation to deeper structures[26][27]
• Pain and paresthesia from perineural invasion[24][25]
• Facial nerve weakness (cranial nerve VII palsy), particularly with parotid tumors[26][27]
• Trismus, when the parapharyngeal space is involved[24]
• Cervical lymphadenopathy[25]
• Mucosal ulceration or a bluish hue (characteristic of MEC)[24]

Minor Salivary Gland Tumors of the Oral Cavity

Intraoral tumors most commonly arise on the posterior hard palate as a submucosal, dome-shaped swelling.[28] Low-grade tumors may be indistinguishable from benign neoplasms on clinical examination. High-grade tumors may show ulceration, fixation, and bone invasion.[24]

Central (Intraosseous) Tumors

Central malignant salivary gland tumors present with jaw swelling, pain, paresthesia of the inferior alveolar nerve, tooth mobility, and occasionally pathologic fracture.[29] The clinical course is often slow, and many cases are discovered incidentally on imaging or initially misdiagnosed as odontogenic cysts.[30] An association with pre-existing odontogenic cysts or impacted teeth has been reported in approximately one-third to one-half of mandibular cases.[6]

Malignant salivary gland tumors affect the jaws through two principal mechanisms: (1) direct invasion from an adjacent minor salivary gland tumor (most commonly palatal) and (2) primary intraosseous (central) origin. The radiographic appearance varies with the mechanism, histologic subtype, and grade.

Location and Distribution

• Minor salivary gland tumors with jaw invasion: Most commonly involve the posterior hard palate and posterior maxilla, reflecting the anatomic distribution of palatal minor salivary glands. Mandibular involvement occurs from retromolar, floor-of-mouth, or buccal gland tumors.[28][31]
• Central (intraosseous) tumors: The mandibular body and premolar-molar-angle region is the characteristic site for central MEC. Maxillary central tumors are less common but do occur. Central AdCC has been reported in the anterior mandible.[6][8][32][33]

Periphery and Shape

• Central MEC commonly presents as a unilocular or multilocular radiolucency. The periphery may be well-defined with a sclerotic border in low-grade tumors, mimicking a benign cystic lesion. Higher-grade tumors tend to show ill-defined or irregular margins.[6][8][9][29]
• Palatal minor salivary gland carcinomas invading bone produce irregular, moth-eaten, or permeative bone destruction rather than a well-corticated border.[31]

Internal Architecture

• Low-grade central MEC characteristically shows a cyst-like radiolucency with internal bony septations creating a multilocular appearance. The septations often lack the well-defined borders seen in ameloblastoma.[9][30]
• Amorphous sclerotic bone within the lesion is a distinctive finding in central MEC and may help distinguish it from odontogenic cysts.[9]
• Intratumoral calcifications are occasionally seen in malignant mixed tumors and have been reported in central MEC of the maxilla; calcification within a palatal tumor is significantly associated with malignancy.[31][34]
• Soft-tissue-density components within an otherwise cystic lesion suggest a solid neoplastic component.[30]

Effects on Teeth and Adjacent Structures

• Tooth displacement and root resorption occur occasionally with central tumors.[6][9]
• Tooth mobility and loss may be presenting features.[29][30]
• Central tumors may be associated with an impacted tooth or arise in the wall of a pre-existing odontogenic cyst, further complicating the radiographic differential.[6][32]

Cortical Involvement, Expansion, and Extent

• Cortical expansion is common in central MEC; cortical perforation with extension into surrounding soft tissue is characteristic of more advanced or higher-grade lesions.[6][9]
• Palatal minor salivary gland carcinomas frequently cause aggressive bone destruction of the hard palate, with extension into the maxillary sinus, nasal cavity, or pterygopalatine fossa.[31]
• CBCT and cross-sectional imaging are superior to panoramic radiography for detecting cortical thinning, cortical destruction, and the true extent of the lesion, particularly in the maxilla where superimposition limits panoramic assessment.[30][35][36]
• AdCC characteristically extends widely through bone marrow before producing detectable cortical destruction, and may spread along the periosteum and dura without obvious bony changes.[24][37]

Recognized Variants and Diagnostic Pitfalls

• Cyst-like central MEC is a well-recognized variant that closely mimics odontogenic cysts or ameloblastoma on panoramic radiography, leading to frequent initial misdiagnosis.[30]
• Rare cases of central MEC present as a mixed radiopaque-radiolucent lesion, simulating a fibro-osseous lesion.[34]
• Panoramic radiography is less reliable for maxillary lesions due to structural superimposition; cross-sectional imaging should be obtained when a maxillary salivary gland malignancy is suspected.[30]

Soft-Tissue Characterization and Tumor Extent

Contrast-enhanced CT delineates the soft-tissue mass, evaluates cortical bone erosion, and detects intratumoral calcifications, which are most often seen in benign and malignant mixed tumors.[3] CT with bone algorithm is particularly useful for assessing cortical erosion adjacent to the temporal bone, skull base, mandible, or palate.[3]

Perineural Spread and Bone Marrow Invasion

MRI is the preferred modality for evaluating perineural tumor spread, bone marrow invasion, and skull base extension.[21][22] Perineural spread is especially prevalent in AdCC, reported in over 50% of patients, and may extend far beyond the apparent tumor margins.[22][24] MRI signal characteristics associated with malignancy include T2 hypointensity, irregular margins, and restricted diffusion.[21][24] Importantly, minor salivary gland carcinomas may infiltrate bone marrow without obvious cortical destruction, a finding best detected on MRI.[37]

Staging and Distant Disease

FDG-PET/CT has a role in staging advanced or high-grade tumors and in detecting recurrence and distant metastases, but its utility is limited by inconsistent FDG avidity—AdCC may be non-avid while benign Warthin tumors may appear hypermetabolic.[21][22] Chest CT is recommended for staging in the setting of advanced high-grade malignancy.[21]

When a malignant salivary gland tumor involves the jaws—whether as a primary intraosseous lesion or by direct invasion from an adjacent minor salivary gland—the radiographic differential depends on whether the presentation is predominantly a cyst-like intraosseous radiolucency or an aggressive destructive process. Central MEC, the most common intraosseous variant, frequently mimics benign odontogenic lesions.

The highest-risk diagnostic pitfall is misidentifying a cyst-like central MEC as a benign odontogenic cyst or glandular odontogenic cyst, leading to conservative treatment (curettage or enucleation) with a recurrence rate approaching 40%.[6] Any jaw cyst with atypical features—internal sclerotic foci, cortical perforation, or mucous cell proliferation on histology—warrants thorough pathologic evaluation including MAML2 FISH testing to exclude central MEC.[7][32]

Major Histologic Subtypes

• Mucoepidermoid carcinoma: Composed of mucous, epidermoid (squamoid), and intermediate cells in varying proportions. Graded as low, intermediate, or high grade based on cystic component, cellular differentiation, growth pattern, and cytologic atypia. The AFIP grading system is widely used. The CRTC1-MAML2 fusion gene, resulting from a t(11;19) translocation, is present in a substantial proportion of cases and is associated with improved survival.[13][16][40][41]
• Adenoid cystic carcinoma: Biphasic tumor of ductal epithelial and myoepithelial cells forming cribriform, tubular, and solid growth patterns. The cribriform pattern with characteristic "Swiss cheese" pseudocystic spaces is the most recognizable morphology. Predominantly solid growth indicates high grade and worse prognosis. The MYB-NFIB or MYBL1-NFIB gene fusion is the hallmark molecular alteration.[16][41][42][43][44][45]
• Salivary duct carcinoma: High-grade adenocarcinoma resembling invasive ductal carcinoma of the breast, frequently showing HER2 amplification and androgen receptor overexpression.[16]
• Carcinoma ex pleomorphic adenoma: Malignant transformation within a pre-existing pleomorphic adenoma; a long-standing mass with recent behavioral change is the classic history.[4][24]

Radiologic-Pathologic Correlation

Central MEC of the jaws shows the same histologic spectrum as its extraosseous counterpart, with low-grade tumors predominating.[8][32] The cystic, mucin-filled spaces of low-grade central MEC correspond to the well-defined radiolucent areas on imaging, while solid tumor nests and sclerotic bone reaction account for internal opacities.[9][34] Areas resembling glandular odontogenic cyst may be found within central MEC, supporting a possible pathogenetic relationship.[7][32]

Molecular Diagnostics Affecting Classification

Tumor-defining gene fusions now serve as powerful diagnostic tools: CRTC1-MAML2 in MEC, MYB-NFIB in AdCC, ETV6-NTRK3 in secretory carcinoma, and EWSR1-ATF1 in clear cell carcinoma.[16][17][41] MAML2 FISH is particularly valuable for distinguishing central MEC from glandular odontogenic cyst.[7]

Workup and Referral

NCCN guidelines recommend a complete head and neck examination, FNA biopsy (image-guided when indicated), and cross-sectional imaging (CT and/or MRI) from skull base to clavicle for suspected malignancy.[10] Chest CT is indicated for advanced or high-grade tumors.[10][21] Multidisciplinary tumor board consultation is strongly recommended.[3] For intraosseous jaw lesions, incisional biopsy with histopathologic and molecular evaluation is essential before definitive treatment.[8][32]

Definitive Treatment

• Surgery is the mainstay of treatment for all resectable malignant salivary gland tumors. Complete resection with adequate margins is the goal; the facial nerve should be preserved when oncologically feasible.[3][10]
  • For central MEC of the jaws, radical surgical excision (segmental resection) is the treatment of choice; conservative treatment (curettage/enucleation) carries a recurrence rate of approximately 40%, compared with approximately 4% after radical resection.[6][7]
  • For minor salivary gland tumors of the palate, partial maxillectomy may be required when bone invasion is present.[31]
• Adjuvant radiotherapy is indicated for high-grade tumors, positive or close margins, perineural invasion, lymph node metastases, lymphovascular invasion, and T3–T4 tumors. IMRT is preferred; proton therapy may be considered when normal tissue constraints cannot be met.[3][10]
• Adjuvant chemoradiotherapy is a category 2B recommendation for high-risk patients.[10][46]
• Adenoid cystic carcinoma is treated with adjuvant RT even in the absence of other adverse features, given its propensity for perineural spread and late recurrence.[10]

Recurrence and Prognosis

• Overall 3-year survival for malignant salivary gland tumors is approximately 80%, with disease-specific survival of approximately 87%.[19]
• Tumor grade, T-stage, and nodal status are the strongest prognostic factors.[5][19]
• AdCC has a characteristically prolonged clinical course with late distant metastases (especially pulmonary); the 5-year survival rate is approximately 90%, but long-term survival declines substantially, with most patients succumbing to disease within 20 years.[47]
• Central MEC of the jaws generally has a favorable prognosis when treated with radical resection; local recurrence occurs in approximately 20% of cases overall, predominantly in low-grade tumors treated conservatively.[7][8]
• Long-term surveillance is essential, particularly for AdCC, given the risk of late recurrence and distant metastasis.[10]

Biomarker Testing for Recurrent/Metastatic Disease

For recurrent or metastatic disease, NCCN guidelines recommend multigene panel testing to assess androgen receptor, HER2, NTRK1/2/3, FGFR, BRAF, RET, MSI/dMMR, TMB, and PD-L1 status to guide systemic therapy options.[10]